Edwards Q2 sales flat at $1.37B; lowers FY2022 outlook on FX, staffing

Edwards Lifesciences Corp

2022-Q2 EPS reported $1.24 revenue$2,715,100,000

Q2 sales $1.37B flat YoY; underlying growth 5%. GAAP EPS $0.65, adjusted EPS $0.63.
TAVR sales $907M (+1% reported, +5% underlying); TMTT $28M; Surgical $229M; Critical Care $211M.
Full-year sales guidance lowered to $5.35-$5.55B; adjusted EPS guided to low end of $2.50-$2.65.
Q2 share repurchases of $355M; Board approved new authorization with $1.9B remaining.
Adjusted gross margin improved to 80.5% from 75.9%, helped by FX hedge gains.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.